Cargando…

Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis

BACKGROUND: Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubbioso, Raffaele, Bove, Marco, Boccia, Daniele, D’Ambrosio, Vincenzo, Nolano, Maria, Manganelli, Fiore, Iodice, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363320/ https://www.ncbi.nlm.nih.gov/pubmed/35419681 http://dx.doi.org/10.1007/s00415-022-11114-x

Ejemplares similares

Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study
por: Dubbioso, Raffaele, et al.
Publicado: (2023)

Quantitative Sensory Testing in Late-Onset ATTRv Presymptomatic Subjects: A Single Center Experience
por: Tozza, Stefano, et al.
Publicado: (2022)

Value of Antibody Determinations in Chronic Dysimmune Neuropathies
por: Tozza, Stefano, et al.
Publicado: (2022)

The neuropathy in hereditary transthyretin amyloidosis: A narrative review
por: Tozza, Stefano, et al.
Publicado: (2021)

The impact of symptoms on daily life as perceived by patients with Charcot-Marie-Tooth type 1A disease
por: Tozza, Stefano, et al.
Publicado: (2021)

Primary Progressive Multiple Sclerosis Under Anti-TNFα Treatment: A Case Report
por: Iovino, Aniello, et al.
Publicado: (2020)

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
por: Lanzillo, Roberta, et al.
Publicado: (2022)

Correlation between Retinal Vascularization and Disease Aggressiveness in Amyotrophic Lateral Sclerosis
por: Cennamo, Gilda, et al.
Publicado: (2022)

Alteration of interoceptive sensitivity: expanding the spectrum of behavioural disorders in amyotrophic lateral sclerosis
por: Moretta, Pasquale, et al.
Publicado: (2022)

Fast Intracortical Sensory-Motor Integration: A Window Into the Pathophysiology of Parkinson’s Disease
por: Dubbioso, Raffaele, et al.
Publicado: (2019)

One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
por: Ruggiero, Lucia, et al.
Publicado: (2018)

Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP)
por: Dubbioso, Raffaele, et al.
Publicado: (2020)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

The emotional impact of COVID-19 outbreak in amyotrophic lateral sclerosis patients: evaluation of depression, anxiety and interoceptive awareness
por: De Lucia, Natascia, et al.
Publicado: (2020)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Brain Plasticity in Charcot-Marie-Tooth Type 1A Patients? A Combined Structural and Diffusion MRI Study
por: Pontillo, Giuseppe, et al.
Publicado: (2020)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
por: Feys, Peter, et al.
Publicado: (2017)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

In vivo evidence of cortical amyloid deposition in the adult form of Niemann Pick type C
por: Esposito, Marcello, et al.
Publicado: (2019)

Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
por: Capasso, Nicola, et al.
Publicado: (2022)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Machine learning for exploring neurophysiological functionality in multiple sclerosis based on trigeminal and hand blink reflexes
por: Biggio, Monica, et al.
Publicado: (2022)

Fitts’ Tapping Task as a New Test for Cognition and Manual Dexterity in Multiple Sclerosis: Validation Study
por: Glavor, Klaudia Duka, et al.
Publicado: (2022)

Behavioral Assessment of Manual Dexterity in Non-Human Primates
por: Schmidlin, Eric, et al.
Publicado: (2011)

An interventional study for improving the manual dexterity of dentistry students
por: Lugassy, Diva, et al.
Publicado: (2019)

Editorial: Promoting Manual Dexterity Recovery After Stroke
por: Lotze, Martin, et al.
Publicado: (2019)

Manual Dexterity in Schizophrenia—A Neglected Clinical Marker?
por: Térémetz, Maxime, et al.
Publicado: (2017)

Impact of Guidance and Multitasking on Manual Dexterity Skills in Dentistry
por: El-Kishawi, Mohamed, et al.
Publicado: (2022)

The Influence of Self-Perception on Manipulative Dexterity in Adults with Multiple Sclerosis
por: Martínez-Piédrola, Rosa M., et al.
Publicado: (2021)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rqamcplgu9nj4lnag7o4sgqred